Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current Clinical Trials in Dry AMD and the Definition of Appropriate Clinical Outcome Measures

1 May 2011

Abstract excerpt

Currently, there is no proven drug treatment for dry age-related macular degeneration (AMD). Several different treatment strategies are being investigated, including complement inhibition, neuroprotection, and visual cycle inhibitors, and novel clinical trial endpoints are being explored. Studies have identified genetic predispositions for dry AMD associated with complement dysfunction. Consequently,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Retinal Development and Disorders
Share to Retinal Diseases and Treatments
Share to Retinal Imaging and Analysis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21609230
DOI: 10.3109/08820538.2011.577132

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current Clinical Trials in Dry AMD and the Definition of Appropriate Clinical Outcome MeasuresPMID 21609230Read ↗

Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option.Semantic proximity Read ↗

Therapeutic targeting of the complement system in ocular diseaseSemantic proximity Read ↗

Complement System and Potential Therapeutics in Age-Related Macular DegenerationSemantic proximity Read ↗

Complement system modulation in age-related macular degeneration: navigating failures, building future successesSemantic proximity Read ↗

The complement system in age-related macular degeneration.Semantic proximity Read ↗

Complement cascade inhibition in geographic atrophy: a review.Semantic proximity Read ↗

Therapeutic targeting of the complement system in age‐related macular degeneration: a reviewSemantic proximity Read ↗

Implications of genetic variation in the complement system in age-related macular degeneration.Semantic proximity Read ↗

Associations between the Complement System and Choroidal Neovascularization in Wet Age-Related Macular DegenerationSemantic proximity Read ↗

Complement, Age-Related Macular Degeneration and a Vision of the FutureSemantic proximity Read ↗

The Dry Form of Age-Related Macular Degeneration (AMD): The Current Concepts of Pathogenesis and Prospects for Treatment.Semantic proximity Read ↗

Complement pathway biomarkers and age-related macular degenerationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.